FT836

FT836 is a next-generation, multiplexed-engineered chimeric antigen receptor (CAR) T-cell therapy developed by Fate Therapeutics. It is designed to uniquely target and bind the α3 domain of major histocompatibility complex (MHC) class I polypeptide-related sequence A and B proteins (MICA/B), which are stress-induced cell-surface proteins expressed on many types of cancer cells but with limited expression on healthy tissue. By targeting the α3 domain, FT836 stabilizes MICA/B expression and induces robust cytolytic killing of tumor cells, overcoming a common resistance mechanism in solid tumors where proteolytic cleavage and shedding of MICA/B at this domain enables immune escape. The product incorporates Fate’s proprietary Sword & Shield technology—a suite of synthetic genetic edits including Alloimmune Defense Receptor (ADR) technology and complete knockout of CD58—to enhance functional persistence, evade host alloreactive immune cells, reduce or eliminate the need for conditioning chemotherapy, and address challenges such as on-target/off-tumor toxicity, effector cell suppression in the tumor microenvironment, tumor heterogeneity, and limited persistence. Preclinical data demonstrate potent anti-tumor activity across a broad array of solid tumors both in vitro and in vivo; cytolytic activity is further enhanced when combined with chemotherapy or radiation therapy[1][4][5][7][8][9].

Other names

FT836 + NxG